Member-only story

Malignant Pleural Mesothelioma: Present Status and Future Directions

Harold Powell

·16.9k Followers· Follow

Published in Jana Aston

7 min read

1.2k View Claps

99 Respond

Save

Listen

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the lining of the lungs (pleura). It is primarily caused by exposure to asbestos, a fibrous mineral that was widely used in construction and industry in the past. Despite advances in research and treatment, MPM remains a challenging disease with poor prognosis. This article provides a comprehensive overview of the current status of MPM, including its epidemiology, pathology, molecular biology, and treatment options. It also discusses emerging therapeutic strategies and ongoing clinical trials that hold promise for improving patient outcomes.

MPM is a rare but life-threatening disease with an estimated annual incidence of 3,000-4,000 cases in the United States. It typically affects older adults, with a median age at diagnosis between 60 and 70 years. The latency period from asbestos exposure to the development of MPM can be up to several decades, complicating early detection and intervention.

Malignant Pleural Mesothelioma: Present Status and Future Directions

by Jana Aston

5 out of 5

Language	:	English
File size	:	5830 KB
Text-to-Speech	:	Enabled
Screen Reader	:	Supported
Enhanced typesetting	:	Enabled
Print length	:	762 pages

Epidemiology

Asbestos is the leading risk factor for MPM, accounting for more than 80% of cases. Occupational exposure to asbestos was common in the construction, shipbuilding, and mining industries, and many individuals who developed MPM were exposed to asbestos decades ago. However, environmental exposure to asbestos can also occur from exposure to asbestos-containing materials in buildings and from contaminated soil or water.

Pathology

MPM arises from mesothelial cells, which line the pleura and peritoneum. It is classified into three main histological subtypes: epithelioid, sarcomatoid, and biphasic. Epithelioid MPM is the most common subtype, accounting for approximately 60% of cases. Sarcomatoid MPM is a more aggressive subtype and is associated with a worse prognosis. Biphasic MPM has features of both epithelioid and sarcomatoid subtypes.

Molecular Biology

The molecular biology of MPM is complex and involves alterations in multiple genes. Mutations in the tumor protein p53 gene are the most common genetic abnormalities in MPM, occurring in up to 90% of cases. Other commonly mutated genes include those involved in cell cycle regulation, DNA repair, and cell signaling.

Clinical Presentation

The most common symptoms of MPM include shortness of breath, chest pain, and persistent coughing. Other symptoms may include fatigue, weight loss, and night sweats. As the disease progresses, it can lead to pleural effusion (fluid buildup in the lungs),lung collapse, and respiratory failure.

Diagnosis

Diagnosis of MPM requires a comprehensive evaluation that includes history taking, physical examination, imaging studies, and biopsy. Imaging studies such as chest X-ray and computed tomography (CT) scan can help identify pleural lesions and detect pleural effusion. Biopsy is essential for confirming the diagnosis and determining the histological subtype of MPM.

Treatment Options

The treatment of MPM depends on the stage of the disease and the patient's overall health. Surgical resection is the primary treatment option for early-stage MPM. However, surgery is not always feasible in patients with advanced disease. Non-surgical treatments include chemotherapy, radiation therapy, immunotherapy, and targeted therapy.

Chemotherapy

Chemotherapy is the most common treatment for MPM. It involves the use of cytotoxic drugs that kill cancer cells. Common chemotherapeutic agents used for MPM include cisplatin, pemetrexed, and gemcitabine.

Radiation Therapy

Radiation therapy uses high-energy radiation to kill cancer cells. It can be used as a primary treatment or in combination with other therapies. Radiation therapy is often used to relieve pain and other symptoms caused by MPM.

Immunotherapy

Immunotherapy is a type of treatment that boosts the body's immune system to fight cancer. Immune checkpoint inhibitors are a type of immunotherapy that has shown promise in treating MPM. These drugs work by blocking immune checkpoints, which are proteins that suppress the immune system.

Targeted Therapy

Targeted therapy involves the use of drugs that target specific molecules or pathways involved in cancer cell growth and survival. Bevacizumab is a targeted therapy that is approved for the treatment of MPM. It is an anti-angiogenic drug that blocks the formation of new blood vessels that supply tumors with oxygen and nutrients.

Emerging Therapeutic Strategies

Research efforts are ongoing to develop new and more effective treatments for MPM. Promising emerging therapeutic strategies include:

Mesothelin-targeted therapy: Mesothelin is a protein that is overexpressed in MPM. Mesothelin-targeted therapies aim to block the function of mesothelin and kill cancer cells.
PARP inhibitors: PARP inhibitors are drugs that interfere with DNA repair pathways. They have shown activity in treating MPM patients with BRCA1/2 mutations.
Stem cell therapy: Stem cell therapy involves the use of stem cells to regenerate damaged lung tissue and improve lung function in MPM patients.
Gene therapy: Gene therapy involves the use of genetic material to modify the genetic makeup of cancer cells and make them more susceptible to treatment.

Clinical Trials

Numerous clinical trials are currently underway to evaluate the efficacy and safety of new treatments for MPM. These trials offer patients access to experimental therapies that may not be available outside of a clinical setting. Participation in clinical trials is an important way to advance research and contribute to the development of new treatments for MPM.

Prognosis

The prognosis for MPM is generally poor, with a median survival of 12-18 months from diagnosis. The overall survival rate at 5 years is approximately 10%. Prognosis is influenced by factors such as stage of the disease, histological subtype, and patient performance status.

Palliative Care

Palliative care is an important component of MPM management. It focuses on providing comfort and improving quality of life for patients and their families. Palliative care services may include pain management, symptom control, psychological support, and spiritual counseling.

MPM remains a challenging disease with a poor prognosis. However, progress has been made in understanding the molecular biology of MPM and developing new treatment strategies. Emerging therapeutic approaches and ongoing clinical trials hold promise for improving patient outcomes. Continued research and collaboration are essential to advance the field of MPM and provide hope for patients battling this devastating disease.

Malignant Pleural Mesothelioma: Present Status and Future Directions

by Jana Aston

5 out of 5